Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 28, 2013

Filing Date
Filed February 25, 2014
Period End
December 28, 2013
Security
CRL
One revenue dollarkept$0.09
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 25, 2014. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported net sales of $1,165.5 milliona for fiscal 2013, up 3.2% from $1,129.5 million in 2012, with operating income of $151.4 million (13.0% of net sales) versus $165.8 million in 2012.

Net income attributable to common shareholders was $102.8 millionb, or $2.12 diluted EPS, compared with $97.3 million and $2.01 in 2012. Growth came from the Preclinical Services (PCS) segment, where sales rose 5.5% to $458.4 million and operating income increased to $44.1 million, while the Research Models and Services (RMS) segment grew 1.7% to $707.1 million but its operating income fell to $181.3 million from $202.4 million, affected by $13.5 million of accelerated depreciation tied to a California facility consolidation. Cash flow from operations was $209.0 million, and cash and cash equivalents rose to $155.9 million at year-end.

Total debt was $663.0 millionc after a May 2013 refinancing into a $970 million credit facility maturing in May 2018. The company repurchased 3.5 million shares during 2013, and the Board approved $250 million in increases to its share buy-back program, leaving $139.1 million of remaining authorization. The company has not paid cash dividends in the past two years and does not intend to pay them in the foreseeable future.

The filing also discloses an internal investigation, begun in May 2013, into inaccurate billing on certain government contracts within the RMS business. The company has reserved $1.5 milliond for excess amounts billed and states it cannot estimate a loss range beyond that reserve. Management reported that a material weakness in internal control over financial reporting identified as of December 29, 2012 had been remediated, and that internal controls were effective as of December 28, 2013.

Key Highlights

  1. Net sales rose 3.2% to $1,165.5 million in 2013, with PCS growing 5.5% to $458.4 million and RMS growing 1.7% to $707.1 million.
  2. Operating income declined to $151.4 million from $165.8 million, reflecting $15.4 million of accelerated depreciation on two U.S. facilities.
  3. Diluted EPS from net income attributable to common shareholders was $2.12, up from $2.01 in 2012.
  4. Net cash provided by operating activities was $209.0 million, compared with $208.0 million in 2012.
  5. Total debt was $663.0 million at year-end, following a May 2013 $970 million credit facility with a May 2018 maturity; the $350 million 2.25% convertible debentures were retired in June 2013.
  6. The company repurchased 3.5 million shares in 2013 and had $139.1 million remaining under its $1 billion stock repurchase program.
  7. An internal investigation into inaccurate billing on certain U.S. government contracts is ongoing, with a $1.5 million reserve recorded.

Follow one dollar

Of each $1.00 of revenue in FY2013, Charles River Laboratories International kept $0.09.

  1. Revenue$1.17B100.0%
  2. Cost of revenue−$272.8M23.4%
  3. Gross profit$892.8M76.6%
  4. Operating costs−$741.4M63.6%
  5. Operating income$151.4M13.0%
  6. Interest, other & tax−$48.6M4.2%
  7. Net income$102.8M8.8%
Computed from 10-KFY2013filed February 25, 2014Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2013 revenue went

$1.17B
  • Other operating costs: $515.7M, 44% of revenue
  • Cost of revenue: $272.8M, 23% of revenue
  • SG&A: $225.7M, 19% of revenue
  • Net income: $102.8M, 8.8% of revenue
  • Interest, other & tax: $48.6M, 4.2% of revenue

Kept 8.8% as net incomeNet income $102.8M · 8.8%

Full revenue history →

Financial Statements

FY2013 against FY2012

Line itemFY2013FY2012Change
Revenue$1.17B$1.13B+3.2%
Cost of Revenue$272.75M$257.71M+5.8%
Gross Profit$892.78M$871.82M+2.4%
SG&A Expenses$225.69M$208.25M+8.4%
Operating Income$151.40M$165.76M−8.7%
Interest Expense$20.97M$33.34M−37.1%
Net Income$102.83M$97.30M+5.7%
EPS (Basic)$2.15$2.03+5.9%
EPS (Diluted)$2.12$2.01+5.5%
Shares Outstanding (Basic)47.74M47.91M−0.4%
Shares Outstanding (Diluted)48.49M48.41M+0.2%

Frequently Asked Questions

  1. How did Charles River's segments perform in 2013?

    PCS net sales increased 5.5% to $458.4 million, and its operating income rose to $44.1 million from $34.6 million. RMS net sales increased 1.7% to $707.1 million, but its operating income fell to $181.3 million from $202.4 million, due in part to $13.5 million of accelerated depreciation related to a California research model facility consolidation.

  2. What drove the decline in consolidated operating income?

    The filing attributes the reduction in operating income to several factors, including accelerated depreciation expense of $15.4 million related to two U.S. facilities that were consolidated or vacated in 2013, along with lower research model demand in the U.S., Europe and Japan.

  3. What is the company's capital return policy?

    Charles River has not declared or paid cash dividends in the past two years and does not intend to pay cash dividends in the foreseeable future. It repurchased 3.5 million shares on the open market during 2013 and had $139.1 million remaining under its share buy-back authorization at year-end.

  4. What legal or regulatory matters does the filing disclose?

    The company disclosed an investigation, begun in May 2013, into inaccurate billing on certain government contracts in its RMS segment, which it reported to government authorities. It identified approximately $1.5 million in excess amounts billed since January 1, 2007, reserved that amount, and said it cannot estimate a loss range beyond the reserve. It is also in arbitration with a Mauritius supplier of large animal models, and it says it intends to defend that proceeding vigorously.

  5. What was the status of the prior internal control weakness?

    A material weakness in internal control over financial reporting, identified as of December 29, 2012, related to information technology, business processes and financial reporting controls. Management concluded that the material weakness no longer existed as of December 28, 2013, and that internal control over financial reporting was effective as of that date, as audited by PricewaterhouseCoopers LLP.